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Abstract
Objective: A large, population-based case–control cohort was used to test the hypothesis that glutamic
acid decarboxylase-65 (GAD65) and islet antigen-2 autoantibodies (IA-2A) at birth predict type 1
diabetes.
Design and methods: The design was an individually matched case–control study of all Danish type 1
diabetes patients born between 1981 and 2002 and diagnosed before May 1 2004 (median age at
diagnosis was 8.8 years). Dried blood spot samples collected 5 days after birth in the 1981–2002 birth
cohorts and stored at K25 8C were identiﬁed from 2023 patients and from two matched controls
(nZ4042). Birth data and information on parental age and diabetes were obtained from Danish
registers. GAD65A and IA-2A were determined in a radiobinding assay. HLA-DQB1 alleles were
analyzed by PCR using time-resolved ﬂuorescence.
Results: GAD65A and IA-2A were found in 70/2023 (3.5%) patients compared to 21/4042 (0.5%)
controls resulting in a hazard ratio (HR) of 7.49 (P!0.0001). The HR decreased to 4.55 but remained
signiﬁcant (P!0.0003) after controlling for parental diabetes and HLA-DQB1 alleles. Conditional
logistic regression analysis showed a HRof 2.55 (P!0.0001) for every tenfold increase in the levels of
GAD65A and IA-2A. This HR decreased to 1.93 but remained signiﬁcant (P!0.001) after controlling
for parental diabetes and HLA-DQB1 alleles.
Conclusion: These data suggest that GAD65A and IA-2A positivity at birth are associated with an
increased risk of developing type 1 diabetes in Danish children diagnosed between 1981 and 2004.
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Introduction
Type 1 diabetes becomes clinically apparent after a
preclinical period of varying length, during which
immune-mediated destruction reduces the b-cell mass.
This preclinical period varies but appears to be more
rapid in younger individuals (1). Immune-mediated
type 1 diabetes is thought to be determined by the
actions, and possible interactions, of multiple genetic
and environmental factors. At least half of the genetic
risk is determined by alleles of the human leukocyte
antigen (HLA) genes: DQA1, DQB1, and DRB1 (2, 3).
The rest is determined by non-HLA loci (2, 3). It is still
unknown, if, when and what kind of environmental
factors initiate autoimmune b-cell destruction. Viral
infections, nutritional, or other factors might initiate
the type 1 diabetes pathogenetic process already in utero
(4, 5) or postnatally (reviewed in (6)). Reﬂecting b-cell
autoimmunity and possibly destruction, autoantibodies
are often detected against glutamic acid decarboxylase-
65 (GAD65 or GAD2), islet antigen-2 (IA-2), Zn
transporter 8 (ZnT8 or SLC30A10), or insulin, alone
or in combination (7). The risk for type 1 diabetes
increases with an increasing number of autoantibodies,
and one or more autoantibodies are detected in about
90% of newly diagnosed type 1 diabetes patients (4, 8).
Because the autoimmune process contributing to the
development of type 1 diabetes may be initiated long
before the appearance of clinical symptoms (9), ideally
effective prediction and intervention strategies should
be applied as early as possible. It is still not established
whether the presence of islet autoantibodies at the time
of birth impacts the development of type 1 diabetes. In
recent reports, islet autoantibodies were found to be
either protective (10), predictive (4), or without (11)
impact on the development of type 1 diabetes.
Current prospective studies of birth cohorts have
ascertained only a limited number of new patients per
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sufﬁcient statistical power. Furthermore, in the BABY
DIAB (12) and the TRIGR (13) studies, only children
with ﬁrst degree relatives with type 1 diabetes are
included but !15% of new onset patients belong to
this category.
Epidemiological studies indicate that perinatal factors
such as gestational infections, pre-eclampsia, birth
weight (BW), and maternal age affect the risk for
type 1 diabetes (6, 14, 15). However, in a recent Danish
study, no signiﬁcant correlation between BW, maternal
age, and type 1 diabetes risk was detected (16). Owing
to the complex nature of type 1 diabetes pathogenesis,
combination of immunological and demographical
parameters in a large population-based case–control
study may improve the identiﬁcation of factors that
predict type 1 diabetes.
The aim of the present study was to estimate the
effect of GAD65A and IA-2A at the time of birth on
type 1 diabetes risk up to 23 years of age. Interaction
between islet autoantibody status and risk alleles
(HLA-DQB1), BW, birth length (BL), gestational age
(GA), parental age and diabetes status, and age at
diabetes onset is tested.
Materials and methods
Samples
The study was an individually matched population-
based case–control study (17). All type 1 diabetes cases
born in Denmark between January 1 1981 and
December 31 2002, and diagnosed at 23 years or
younger, were identiﬁed from the National Patient
Register. These data were validated against an indepen-
dent registry (DSBD, www.DSBD.dk) (17). A total of
2023 cases with available dried blood spots (DBSs)
samples were identiﬁed. The median age at diagnosis
w a s8 . 8y e a r s( r a n g e1 – 2 2y e a r s ) .T w oc o n t r o l
individuals matched by date and place of birth were
selected using the databank of DBSs (see below). Control
individuals were required to be alive and free of diabetes
at the date of diagnosis of the matching cases.
Information on parental diabetes status (at the time of
delivery), including type of diabetes, was obtained from
the National Patient Registry, and information on birth
data (BW, BL, and GA) was obtained from the Danish
Birth Register.
Surplus DBS samples collected for the Danish
neonatal screening program have since 1981 been
stored at K25 8C in a central repository (18). Samples
in the repository were organized by date of birth and
place of birth. The two samples placed closest to a case
sample were selected as control samples matched by
date- and place of birth. For the present study, two
3.2 mm DBS punches per case and control were
available for analysis of islet autoantibodies.
The protocol was approved by the Danish ethical
committee and the Danish Data Protection Agency. The
study was conducted according to the principles
expressed in the Declaration of Helsinki.
Autoantibody assays
GAD65A and IA-2A were determined in a previously
described radiobinding assay (17). The DBSs were
limited in availability, which made it necessary to
combine
35S-methione-labeled GAD65 and IA-2 in one
assay similar to previous reports (19). Islet autoanti-
body levels were measured in counts per minute.
Relative units (RU) were calculated as described in
detail elsewhere (20). Samples from matched cases and
controls were always measured in the same assay run.
In the present and in previous (19, 21) investigations of
islet autoantibodies eluted from DBSs, the sensitivity for
GAD65Ab and IA-2Ab assays was assessed in 1950
consecutively diagnosed (May 2005–September 2008)
type 1 diabetes patients from all over Sweden. Using a
cut-off value at 31 RU/ml (99.5 percentile for control
population of Swedish children), we found that
1317/1950 patients had GADA, i.e. representing 68%
diagnostic sensitivity. In the IA-2A assay, we used a cut-
off value of 5 RU/ml (99.5 percentile for control
population of Swedish children) and found that
1465/1950 patients had IA-2A representing 75%
sensitivity. Our laboratory participates in the Diabetes
Autoantibody Standardization Program (DASP) (22),
and in the 2007 serum exchange, the workshop
sensitivity and speciﬁcity for GAD65Ab were 82 and
96% and the workshop sensitivity and speciﬁcity for
IA-2Ab were 65 and 99% respectively.
Genotyping
Time-resolved ﬂuorometry was used for identiﬁcation of
HLA-DQB1 alleles (02, 0301, 0302, 0304, 0602,
0603, and 0604) as described in details (23).
Statistical analysis
We used conditional logistic regression for matched sets
to analyze the data (SAS proc phreg). Because controls
were sampled as being alive at the date of diagnosis of
the case, the odds ratios from the analysis are estimates
of hazard ratios (HRs) for type 1 diabetes.
Values of antibody measurements were log10 trans-
formed in order to provide estimates of the effect of a
tenfold increase of the antibody level.
Since case and control samples were matched by date
of birth and hence age, date of sampling, and storage
time, the effect of these variables cannot be assessed in
this study. Interaction between autoantibody levels and
these variables could in principle be assessed, but we
have no reason to suspect that calendar time or storage
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cases and controls. Additional perinatal and demo-
graphic factors (BW, BL, GA, parental age, parental
diabetes, and gender), and genotypes, were included
into multiple regression models.
Confounders
Perinatal factors (BW, BL, and GA), demographic factors
(parental age and gender), parental type 1 diabetes, and
HLA-DQB1 genotype were considered possible confoun-
ders for the effect of islet autoantibodies on type 1
diabetes risk. Interaction models: the fact that the origin
of islet autoantibodies detected in newborns most
probably is of maternal origin was the rationale for
testing for interaction between the effect of maternal
type 1 diabetes and the presence of islet autoantibodies
on type 1 diabetes risk. Separate effects for mothers with
and without type 1 diabetes were considered.
Results
A total of 70/2023 (3.5%) of the cases were positive
in the GAD65A and IA-2A assays (HRZ7.49,
P!0.0001). No signiﬁcant change in frequency of
antibody positivity and/or titers (measured in RU) by
storage time could be detected (data not shown). The
frequencyof mothers and fathers with type 1 diabetes in
the positive compared to negative islet autoantibody
cases and controls is shown in Table 1. A total of 27
cases had mothers and 2 cases had fathers with type 1
diabetes compared to 8 and 1 respectively among the
islet autoantibodies positive controls (n.s.). The HR 7.49
for positive islet autoantibodies status at birth decreased
to HR 5.75 when controlling for parental diabetes. More
islet autoantibody-positive cases, 27/70 (39%) than
27/1957 (1.4%) islet autoantibody-negative cases
(P!0.0001), had a mother with type 1 diabetes.
Gender had no signiﬁcant effect on the riskof developing
type 1 diabetes. We also tested whether high-risk
HLA-DQB1 alleles were confounders. The HR decreased
to 4.55 but remained signiﬁcant (P!0.0003) after
controlling for parental diabetes and HLA-DQB1 alleles.
TheconditionallogisticregressionanalysisshowedaHR
of2.55foreverytenfoldincreaseofRUintheGAD65Aand
IA-2A assays (P!0.0001). We next analyzed whether
perinatal and demographic factors modiﬁed the latter HR
(Table 2). Not only maternal (HRZ4.2; P!0.0001) but
also paternal (HRZ7.3; P!0.001) diabetes patients were
signiﬁcant predictors, and also maternal age showed a
signiﬁcant effect (HRZ1.2/10 years; P!0.03). Including
parental type 1 diabetes and maternal age into the model
reduced the type 1 diabetes risk from HR 2.55 to HR 2.23;
however, the risk remained signiﬁcant (P!0.0001).
Including both DQB1 alleles as well as parental diabetes
and maternal age into the model reduced the increased
type 1 diabetes risk to HR 1.93, still indicating that islet
autoantibody positivity had an independent risk
(P!0.001). There was no difference in autoantibody
(aab) positivity in relation to age of type 1 diabetes
diagnosis.In total,57% ofaab-positivecaseswereyounger
than 10 years of age (20% !5y e a r s ,3 7 %5 – 9y e a r s ) ,
compared to all 1957 aab-negative cases, where the age
distribution was similar: 58% of cases were diagnosed
below 10 years of age (24% !5 years, 34% 5–9 years).
Discussion
The present study shows that GAD65A and IA-2A
positivity at birth were associated with a 7.5-fold
increased risk for developing type 1 diabetes in this
cohort of Danish children. Every tenfold increase in
GAD65A and IA-2A levels at birth increased the risk for
development of type 1 diabetes by a factor 2.55. Thus,
both presence and titers of GAD65A and IA-2A had a
strong risk-increasing effect. Maternal type 1 diabetes
Table 1 Distribution of parental diabetes status per autoantibody status (in combined assay) and per
case/control status. Diabetes status is subdivided into numbers of mothers and fathers with type 1
diabetes, with other types of diabetes (type 2 diabetes, latent autoimmune diabetes in adults (LADA),
gestational diabetes), unspeciﬁed diabetes (uncertain of diabetes type), or without diabetes (no).
Autoantibody status (combined)
Cases Controls
Positive Negative Positive Negative
Diabetes
status Mothers Fathers Mothers Fathers Mothers Fathers Mothers Fathers
Type 1 27 2 27 120 8 1 14 37
Other 3 1 21 25 1 0 36 44
No 40 67 1904 1804 12 20 3969 3936
Unspeciﬁed 0 0 2 5 0 0 2 4
Unknown 0 0 3 3 0 0 0 0
Total (n) 70 70 1957 1957 21 21 4021 4021
Altogether (casesCcontrols) there were 6069 mothers and 6069 fathers.
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approximately one-ﬁfth of the risk increase associated
with GAD65A and IA-2Apresence.That the presence of
isletautoantibodiesatthetimeofbirthmaybepredictive
for later type 1 diabetes development was suggested by
Lindberg et al. (4), who studied cord blood samples from
85 children who later developed type 1 diabetes and
321 control subjects. Our approach to test the validityof
the previous observation (4) was to utilize the unique
repository of DBS samples collected for the Danish
neonatal screening program since 1981 (17, 18). This
repository, unique in that the DBSs have been stored at
K25 8C, made it possible to study samples from 2023
type 1 diabetes cases and 4046 matched controls. The
present study is to our knowledge the ﬁrst to show in a
large, validated, and population-based case–control
investigation that islet autoantibodies at birth were
associatedwithincreasedtype1diabetesrisklaterinlife.
Do the islet autoantibodies identiﬁed in the 5-day-old
newborns have maternal origin or are they produced by
the newborn themselves? It is well known that during
second trimester of pregnancy, maternal immuno-
globulin is actively transported across the placenta to
the fetus (24). Antibody transport accelerates during
the last trimester until birth, and IgG concentrations
in the fetus exceed those of the mother (25). Neither
maternal IgA nor IgM are transferred to the fetus. In the
present study, detected GAD65A and IA-2Awere mostly
of the IgG subclass as Sepharose Protein A was used to
separate free from antibody-bound labeled autoantigen.
From vaccination studies (26), it is known that the
ability of newborns to generate IgG responses increases
over the ﬁrst year, but adult responses to protein
antigens are not achieved until 12–24 months of age.
We assume that the GAD65A and IA-2A we measured
were transferred from the mother to the child. It is
therefore possible that subclinical islet autoimmunity in
the pregnant mother may explain the increased risk for
type 1 diabetes in her offspring.
Islet autoantibodies are strongly associated with
HLA-conferred diabetes susceptibility both in families
and in the general population (27). We asked whether
autoantibody positivity is a surrogate marker of HLA-
deﬁned diabetes predisposition in the current study
population. It is likely that the autoantibody-positive
non-diabetic mothers carry HLA risk genotypes for type
1 diabetes at a higher frequency than the autoantibody-
negative mothers. Accordingly, the autoantibody-
positive mothers may also transfer such genotypes to
their child resulting in an increased diabetes risk in the
offspring. The type 1 diabetes risk ascribed to the
presence of GAD65A and IA-2A was reduced but still
remaining signiﬁcant when HLA-DQB1 genotypes were
included into the model. It cannot be excluded that
other genetic factors, with lower risk, may contribute to
the risk of type 1 diabetes in the offspring to islet
autoantibody-positive mothers. We conclude that the
presence of islet autoantibodies at the time of birth
predicts type 1 diabetes risk regardless of HLA risk
genotypes and maternal diabetes.
In the present study, only one-ﬁfth of the increase in
disease risk related to the presence of GAD65A and IA-
2A was actually related to maternal diabetes. However,
GAD65A- and IA-2A-positive cases without diabetic
mothers may be the most intriguing observation.
Follow-up studies of these mothers will be of interest
as gestational islet autoantibodies may increase the risk
for post partum type 1 diabetes (28, 29). In these
mothers, in utero infections (30) or other stressors (14)
could either have had direct impact on b cells or may
have caused b-cell damage by initiating a strong
proinﬂammatory immune response. Furthermore,
about 50% of those children whose mothers have
type 1 diabetes were still GAD65A and IA-2A negative
at the time of birth. Mothers diagnosed with type 1
diabetes have variable duration of their diabetes, and
may become negative for autoantibodies prior to or
during their pregnancy (31).
A possible weakness to our study is that we may in
particular detect cases that had an early age at
diagnosis. However, the GAD65A- and IA-2A-related
effect on type 1 diabetes risk was found to be similar in
children below and above 10 years of age at type 1
diabetes onset. Proportions of GAD65A- and IA-2A-
positive cases with young diagnosis out of all GAD65A-
and IA-2A-positive cases, and of young GAD65A- and
IA-2A-positive cases out of all cases, were similar. In the
DIPP study (27), the majorityof children who developed
ﬁrst multiple islet autoantibodies and then type 1
diabetes had an appearance of one or more islet
autoantibody below the age of 5 years. In the DAISY
study (11), no association could be shown between the
presence of islet autoantibodies at birth and type 1
diabetes risk. In the BABY DIAB study (10), in contrast,
the presence of maternal islet autoantibodies was
suggested as protective against type 1 diabetes before
the age of 8 years. Insulin autoantibodies (IAA)
Table 2 Inclusion of perinatal data and parental diabetes. The
variables in the table may be responsible for some of the effects on
type 1 diabetes risk falsely ascribed to the presence of autoanti-
bodies, i.e. may be confounders.
Variables
Hazard
ratio (HR) 95% CI P!
Tenfold increase in RU
autoantibodies
2.23 1.66–3.01 0.0001
Birth length – per cm 0.91 0.97–1.04 0.91
Birth weight – per kg 1.03 0.87–1.23 0.71
Gestational age – per week 1.00 0.95–1.04 0.84
Maternal age – per 10 years 1.22 1.02–1.489 0.03
Paternal age – per 10 years 0.93 0.80–1.09 0.37
Sex, male versus female 1.05 0.93–1.20 0.42
Maternal type 1 diabetes 4.23 2.29–7.81 0.0001
Paternal type 1 diabetes 7.31 4.71–11.35 0.0001
By inclusion into the statistical model, the individual increases/decreases in
type 1 diabetes risk belonging to each variable are listed including the level of
signiﬁcance (P value) and conﬁdence interval (CI).
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other hand, were associated with an increased type 1
diabetes risk. Owing to limited DBS material, we were
also not able to analyze IAA in the present study. Much
larger cohort studies will be needed to further analyze
the risk of islet autoantibodies at the time when DBSs
are obtained for perinatal screening of monogenic
diseases. In such studies, it will also be important to
obtain data on maternal islet autoantibodies as well as
HLA alleles and non-HLA genetic risk factors (2, 32).
The individually matched case–control design implies
that control subjects were selected as not having
diabetes at the date of diagnosis of the corresponding
case. None of the control subjects developed type 1
diabetes in the follow-up period; nevertheless, we
cannot exclude some subjects of the control group,
which may develop type 1 diabetes later in life.
However, this is unlikely to affect the overall conclusion
of the study.
In the present case cohort, speciﬁcity was very high,
i.e. seven times as many future type 1 diabetes patients
were GAD65A and/or IA-2A positive at birth compared
to the control group. Because the number of cases and
controls in our study population does not correspond
to the real distribution in a background population
(i.e. the ratio of cases to controls in the study is much
higher), we are not able to draw conclusions for how
speciﬁc and sensitive the presence of GAD65A and
IA-2A at birth were for prediction of type 1 diabetes in
the general population.
In conclusion, the present study represents a large
population-based case–control study demonstrating
that GAD65A and IA-2A positivity at birth suggest an
increased risk of developing type 1 diabetes at any age
before 23 years.
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